Published in Sarcoma on October 14, 2010
Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol (2013) 0.90
Identification of a blood-borne miRNA signature of synovial sarcoma. Mol Cancer (2015) 0.86
Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res (2012) 0.82
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation. Int J Exp Pathol (2015) 0.78
Extraosseous Ewing Sarcoma: Diagnosis, Prognosis and Optimal Management. Indian J Surg (2015) 0.76
Rare adrenal gland incidentaloma: an unusual Ewing's sarcoma family of tumor presentation and literature review. BMC Urol (2017) 0.75
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med (2003) 8.48
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol (1999) 4.70
Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol (2000) 4.15
Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene (1990) 3.74
Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol (2000) 3.35
Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res (2005) 3.33
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell (2006) 3.29
Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol (2005) 3.20
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol (1998) 3.10
The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene (2003) 3.10
Mesenchymal stem cell features of Ewing tumors. Cancer Cell (2007) 3.04
Ewing's sarcoma. Lancet Oncol (2010) 2.96
Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J (1993) 2.91
Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer (1979) 2.76
Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol (1990) 2.48
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol (2009) 2.44
EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res (2008) 2.39
Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol (1993) 2.24
Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol (2000) 2.24
Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol (2005) 2.19
Comparison of Ewing's sarcoma of bone and peripheral neuroepithelioma. An immunocytochemical and ultrastructural analysis of two primitive neuroectodermal neoplasms. Arch Pathol Lab Med (1994) 2.18
Identification of cancer stem cells in Ewing's sarcoma. Cancer Res (2009) 2.15
Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci U S A (2008) 2.06
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01
The ETS-domain transcription factor family. Int J Biochem Cell Biol (1997) 1.94
Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer (2007) 1.93
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol (2010) 1.88
Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer (1975) 1.85
EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev (2010) 1.81
NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res (2006) 1.80
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol (2000) 1.77
Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol (1987) 1.68
Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol (1998) 1.66
A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle (2007) 1.66
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol (2005) 1.66
Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2010) 1.65
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene (2010) 1.62
Adamantinoma-like Ewing's sarcoma: genomic confirmation, phenotypic drift. Am J Surg Pathol (1999) 1.61
Peripheral and central primitive neuroectodermal tumors. A nosologic concept seeking a consensus. Arch Pathol Lab Med (1986) 1.58
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol (1999) 1.58
Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res (2006) 1.57
Soft tissue tumors associated with EWSR1 translocation. Virchows Arch (2010) 1.50
FUS/ERG gene fusions in Ewing's tumors. Cancer Res (2003) 1.50
Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol (1983) 1.49
Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer (2008) 1.49
Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol (1998) 1.47
EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res (2005) 1.46
Translocation-related sarcomas. Semin Oncol (2009) 1.45
Cancer biology: summing up cancer stem cells. Nature (2005) 1.40
Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch (2009) 1.39
The neuroectodermal tumor of bone. Am J Surg Pathol (1984) 1.39
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol (2004) 1.37
Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer (2010) 1.33
Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol (1996) 1.32
Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn (2007) 1.31
Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res (2009) 1.29
Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol (2003) 1.29
Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol (1997) 1.29
Prognostic impact of P53 status in Ewing sarcoma. Cancer (2000) 1.27
Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res (2003) 1.25
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol (1998) 1.23
Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. A report from the Kiel Pediatric Tumor Registry. Cancer (1991) 1.23
Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer (1997) 1.22
Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res (1987) 1.21
Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer (2010) 1.20
CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer (2010) 1.20
Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. J Mol Diagn (2007) 1.19
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer (2008) 1.18
Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones. Int J Radiat Oncol Biol Phys (1985) 1.17
Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol (2006) 1.17
Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol (1998) 1.14
Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma. Cell Cycle (2006) 1.14
Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer (1997) 1.14
7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem (2005) 1.14
Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer (2002) 1.13
Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene (2004) 1.12
CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest (2010) 1.10
Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types. Am J Pathol (1996) 1.09
Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol (2007) 1.08
Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene. Cancer Res (1995) 1.08
Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer (2000) 1.08
Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer (2004) 1.08
Cytochrome P450 and anticancer drugs. Curr Drug Metab (2006) 1.08
Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol (2005) 1.07
Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol (2009) 1.07
Pathologic features of extraosseous Ewing's sarcoma: a report from the Intergroup Rhabdomyosarcoma Study. Hum Pathol (1988) 1.06
Localised Ewing sarcoma/PNET of bone--prognostic factors and international data comparison. Med Pediatr Oncol (2002) 1.05
Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int J Cancer (1987) 1.05
Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer (1999) 1.05
Immunohistochemical detection of EWS and FLI-1 proteinss in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol (2001) 1.05
Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene (2004) 1.05
Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer (2009) 1.04
Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol (2004) 1.04
The murine CD99-related molecule CD99-like 2 (CD99L2) is an adhesion molecule involved in the inflammatory response. Cell Commun Adhes (2007) 1.03
Therapy for localized Ewing's sarcoma of bone. J Clin Oncol (1989) 1.03
Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol (1999) 1.01
Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer (2011) 1.01
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol (2009) 2.44
The problems and promise of central pathology review: development of a standardized procedure for the Children's Oncology Group. Pediatr Dev Pathol (2007) 1.95
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol (2007) 1.67
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma (2014) 1.43
Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer (2008) 1.40
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother (2015) 1.04
Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril (2008) 1.02
A mouse model of lethal synergism between influenza virus and Haemophilus influenzae. Am J Pathol (2009) 0.99
A proposed method to adjust for selection bias in cohort studies. Am J Epidemiol (2010) 0.99
Stage at diagnosis and mortality in women with pregnancy-associated breast cancer (PABC). Breast Cancer Res Treat (2013) 0.91
A method to visualize and adjust for selection bias in prevalent cohort studies. Am J Epidemiol (2011) 0.90
Characterization of the chromosome 1q41q42.12 region, and the candidate gene DISP1, in patients with CDH. Am J Med Genet A (2010) 0.90
BIRC5 expression is a poor prognostic marker in Ewing sarcoma. Pediatr Blood Cancer (2012) 0.89
Angiosarcomas arising in the viscera and soft tissue of children and young adults: a clinicopathologic study of 15 cases. Am J Surg Pathol (2009) 0.84
Rebuttal to editorial saying cancer survival statistics are misleading. BMJ (2011) 0.82
Clinical utility gene card for: Alveolar rhabdomyosarcoma. Eur J Hum Genet (2011) 0.80
Unusual presentation of congenital infantile fibrosarcoma in seven infants with molecular-genetic analysis. Fetal Pediatr Pathol (2011) 0.80
Mortality after pediatric lung transplantation: autopsies vs. clinical impression. Pediatr Pulmonol (2004) 0.79
MAOA haplotypes associated with thrombocyte-MAO activity. BMC Genet (2005) 0.78
Sinonasal malignancies in Sweden 1960-2010; a nationwide study of the Swedish population. Rhinology (2015) 0.78
A novel t(8;13)(q21;q22) translocation in a pediatric lipoma. Cancer Genet (2011) 0.78
Lymphoma arising from a calcinotic lesion in a patient with juvenile dermatomyositis. Pediatr Dermatol (2009) 0.75
[Cancer researchers need statistical uncertainty!]. Lakartidningen (2004) 0.75